JP2013540791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540791A5 JP2013540791A5 JP2013535408A JP2013535408A JP2013540791A5 JP 2013540791 A5 JP2013540791 A5 JP 2013540791A5 JP 2013535408 A JP2013535408 A JP 2013535408A JP 2013535408 A JP2013535408 A JP 2013535408A JP 2013540791 A5 JP2013540791 A5 JP 2013540791A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- vegf
- inhibitor
- methyl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 241000700159 Rattus Species 0.000 claims 4
- 208000014245 Ocular vascular disease Diseases 0.000 claims 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 3
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 claims 3
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 239000000902 placebo Substances 0.000 claims 2
- 229940068196 placebo Drugs 0.000 claims 2
- -1 2,3-dimethyl-2H-indazol-6-yl Chemical group 0.000 claims 1
- UQNSWWUIPYVMTB-JTQLQIEISA-N 5-[[(6s)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxylic acid Chemical group C1=C2N(C(O)=O)C=CC2=CC(OC2=NC=NC3=C2C[C@@H](NC3)C)=C1 UQNSWWUIPYVMTB-JTQLQIEISA-N 0.000 claims 1
- FTKFKTZZLRFVEP-AWEZNQCLSA-N 5-[[(6s)-7-acetyl-6-methyl-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-4-yl]oxy]-n-(5-cyclopropyl-1,2-oxazol-3-yl)indole-1-carboxamide Chemical compound C([C@@H](N(C1)C(C)=O)C)C2=C1N=CN=C2OC(C=C1C=C2)=CC=C1N2C(=O)NC(=NO1)C=C1C1CC1 FTKFKTZZLRFVEP-AWEZNQCLSA-N 0.000 claims 1
- YSIOGYDLXTWENO-UHFFFAOYSA-N 5-[[4-[(2,3-dimethylindazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Chemical group C1=CC2=C(C)N(C)N=C2C=C1CNC(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 YSIOGYDLXTWENO-UHFFFAOYSA-N 0.000 claims 1
- IOYGAWXBNPFOKF-UHFFFAOYSA-N 6-(6-aminopyrimidin-4-yl)oxy-n-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide Chemical compound C1=NC(N)=CC(OC=2C=C3C=CC=C(C3=CC=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=N1 IOYGAWXBNPFOKF-UHFFFAOYSA-N 0.000 claims 1
- JNLSTLQFDDAULK-UHFFFAOYSA-N 6-[6-(hydroxymethyl)pyrimidin-4-yl]oxy-n-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide Chemical compound C1=NC(CO)=CC(OC=2C=C3C=CC=C(C3=CC=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=N1 JNLSTLQFDDAULK-UHFFFAOYSA-N 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- CXHHBESKHSJGOL-UHFFFAOYSA-N n-[5-(1-methylcyclopropyl)-1h-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide Chemical compound C1=C(NC(=O)N2C3=CC=C(OC=4C=5CCNCC=5N=CN=4)C=C3C=C2)NN=C1C1(C)CC1 CXHHBESKHSJGOL-UHFFFAOYSA-N 0.000 claims 1
- WFJQCQNBWDAYSK-AWEZNQCLSA-N n-[5-(1-methylcyclopropyl)-1h-pyrazol-3-yl]-5-[[(6s)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxamide Chemical compound C([C@@H](NC1)C)C2=C1N=CN=C2OC(C=C1C=C2)=CC=C1N2C(=O)NC(NN=1)=CC=1C1(C)CC1 WFJQCQNBWDAYSK-AWEZNQCLSA-N 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40721810P | 2010-10-27 | 2010-10-27 | |
| US61/407,218 | 2010-10-27 | ||
| PCT/EP2011/068682 WO2012055884A1 (en) | 2010-10-27 | 2011-10-25 | Dosing regimes for the treatment of ocular vascular disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540791A JP2013540791A (ja) | 2013-11-07 |
| JP2013540791A5 true JP2013540791A5 (enExample) | 2014-12-04 |
| JP5934229B2 JP5934229B2 (ja) | 2016-06-15 |
Family
ID=44913251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535408A Expired - Fee Related JP5934229B2 (ja) | 2010-10-27 | 2011-10-25 | 眼血管疾患の処置のための投与計画 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130197016A1 (enExample) |
| EP (1) | EP2632458B1 (enExample) |
| JP (1) | JP5934229B2 (enExample) |
| KR (1) | KR20140008303A (enExample) |
| CN (1) | CN103167873A (enExample) |
| AU (1) | AU2011322597B2 (enExample) |
| BR (1) | BR112013009701A2 (enExample) |
| CA (1) | CA2814439A1 (enExample) |
| EA (1) | EA022873B1 (enExample) |
| ES (1) | ES2547145T3 (enExample) |
| MX (1) | MX2013004782A (enExample) |
| WO (1) | WO2012055884A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| HK1217092A1 (zh) * | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| US10174006B2 (en) | 2013-06-06 | 2019-01-08 | Novartis Ag | Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease |
| EP3988992A1 (en) | 2013-11-15 | 2022-04-27 | Tangible Science, Inc. | Contact lens with a hydrophilic layer |
| JPWO2015147204A1 (ja) * | 2014-03-27 | 2017-04-13 | 国立大学法人京都大学 | 血管新生増殖因子を阻害する医薬組成物 |
| CN107206119B (zh) | 2014-12-09 | 2021-01-29 | 实体科学公司 | 具有生物相容性层的医疗设备涂层 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0209216B8 (pt) | 2001-04-27 | 2021-05-25 | Kyowa Hakko Kirin Co Ltd | derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| DK1954281T3 (da) | 2005-11-29 | 2011-05-16 | Glaxosmithkline Llc | Fremgangsmåde til cancerbehandling |
| JP2010509369A (ja) * | 2006-11-10 | 2010-03-25 | ジェネンテック インコーポレイテッド | 加齢黄斑変性症を処置するための方法 |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
-
2011
- 2011-10-25 WO PCT/EP2011/068682 patent/WO2012055884A1/en not_active Ceased
- 2011-10-25 BR BR112013009701A patent/BR112013009701A2/pt not_active IP Right Cessation
- 2011-10-25 MX MX2013004782A patent/MX2013004782A/es not_active Application Discontinuation
- 2011-10-25 EP EP11779606.0A patent/EP2632458B1/en not_active Not-in-force
- 2011-10-25 AU AU2011322597A patent/AU2011322597B2/en not_active Ceased
- 2011-10-25 US US13/878,678 patent/US20130197016A1/en not_active Abandoned
- 2011-10-25 ES ES11779606.0T patent/ES2547145T3/es active Active
- 2011-10-25 CN CN2011800496321A patent/CN103167873A/zh active Pending
- 2011-10-25 EA EA201390618A patent/EA022873B1/ru not_active IP Right Cessation
- 2011-10-25 JP JP2013535408A patent/JP5934229B2/ja not_active Expired - Fee Related
- 2011-10-25 KR KR1020137010744A patent/KR20140008303A/ko not_active Withdrawn
- 2011-10-25 CA CA2814439A patent/CA2814439A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540791A5 (enExample) | ||
| CN103458690B (zh) | 治疗肺动脉高压的组合物和方法 | |
| CN107223125B (zh) | sGC刺激剂 | |
| ES2651162T3 (es) | Antagonistas fluorados de integrina | |
| JP2022116191A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| RU2016121150A (ru) | Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума | |
| CN102480957A (zh) | 治疗癌症及非肿瘤病症的方法 | |
| AU2024202380A1 (en) | Methods of preventing or treating ophthalmic diseases | |
| TWI516266B (zh) | 用於治療青光眼及高眼壓症之腺苷ａ１促效劑 | |
| TW200815416A (en) | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases | |
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| WO2019030540A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| JP2017527600A5 (enExample) | ||
| RU2019114205A (ru) | Способы лечения глазного заболевания с применением ингибиторов csf-1r | |
| CN102488674B (zh) | 一种异甘草素滴眼液及其制备方法 | |
| JPWO2014157727A1 (ja) | 眼疾患治療剤 | |
| KR20140135215A (ko) | 특정한 종양의 치료를 위한 (rs)-s-시클로프로필-s-(4-｛[4-｛[(1r, 2r)-2-히드록시-1-메틸프로필]옥시｝-5-(트리플루오로메틸)피리미딘-2-일]아미노｝페닐)술폭시미드의 용도 | |
| JP2019534269A5 (enExample) | ||
| US20210121447A1 (en) | The Use of Non-Steroidal Mineralocorticoid Receptor Antagonists Alone or in Combination for the Treatment of Muscular or Neuromuscular Diseases | |
| HK1188138B (en) | Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension | |
| TH64147A (th) | การใช้ประโยชน์ทางเภสัชกรรมของสารยับยั้ง cox-2 ในความผิดปกติของดวงตาที่สื่อโดยการเจริญเติบโตของเส้นโลหิต | |
| EP2776026A1 (en) | 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases |